

IDERA PHARMACEUTICALS, INC.  
Form S-8  
August 05, 2011

As filed with the Securities and Exchange Commission on August 5, 2011

Registration No. 333-\_\_\_\_\_

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM S-8**

**REGISTRATION STATEMENT UNDER  
THE SECURITIES ACT OF 1933**

**Idera Pharmaceuticals, Inc.**

(Exact Name of Registrant as Specified in Its Charter)

**Delaware**

(State or Other Jurisdiction of Incorporation  
or Organization)

**04-3072298**

(I.R.S. Employer  
Identification No.)

**167 Sidney Street**

**Cambridge, Massachusetts**

(Address of Principal Executive Offices)

**02139**

(Zip Code)

**2008 Stock Incentive Plan**

**1995 Employee Stock Purchase Plan**

(Full Title of the Plan)

**Sudhir Agrawal, D. Phil.**

**Chief Executive Officer**

**Idera Pharmaceuticals, Inc.**

**167 Sidney Street**

**Cambridge, Massachusetts 02139**

(Name and Address of Agent For Service)

**(617) 679-5500**

(Telephone Number, Including Area Code, of Agent For Service)

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting  
company

(Do not check if a smaller  
reporting company)

**CALCULATION OF REGISTRATION FEE**

Title of Securities to be Registered	Amount to be Registered(1)	Proposed Maximum Offering Price Per Share	Proposed Maximum Aggregate Offering Price	Amount of Registration Fee
Common Stock, \$0.001 par value	2,300,000 shares(2)	\$1.95(3)	\$4,485,000(3)	\$521.00

per share  
 (including the  
 associated  
 Preferred Stock  
 Purchase Rights),  
 to be issued  
 pursuant to the  
 Idera  
 Pharmaceuticals,  
 Inc. 2008 Stock  
 Incentive Plan, as  
 amended  
 Common Stock,  
 \$0.001 par value  
 per share  
 (including the  
 associated  
 Preferred Stock  
 Purchase Rights),  
 to be issued  
 pursuant to the  
 Idera  
 Pharmaceuticals,  
 Inc. 1995  
 Employee Stock  
 Purchase Plan, as  
 amended

250,000 shares(4)	\$1.95(3)	\$487,500(3)	\$57.00
-------------------	-----------	--------------	---------

- (1) In accordance with Rule 416 under the Securities Act of 1933, as amended, this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.
- (2) Consists of 2,300,000 additional shares issuable under the 2008 Stock Incentive Plan.
- (3) Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act of 1933, as amended, and based upon the average of the high and low prices of the Registrant's Common Stock as reported on the Nasdaq Global Market on August 1, 2011.
- (4) Consists of 250,000 additional shares issuable under the 1995 Employee Stock Purchase Plan.

**STATEMENT OF INCORPORATION BY REFERENCE**

This Registration Statement on Form S-8 is filed to register the offer and sale of (i) an additional 2,300,000 shares of the Registrant's common stock, \$0.001 par value per share, to be issued under the Registrant's 2008 Stock Incentive Plan and (ii) an additional 250,000 shares of the Registrant's common stock, \$0.001 par value per share, to be issued under the Registrant's 1995 Employee Stock Purchase Plan. This Registration Statement incorporates by reference the contents of (i) the registration statement on Form S-8, File No. 333-152669, filed by the Registrant on July 31, 2008, relating to the Registrant's 2008 Stock Incentive Plan and (ii) the registration statements on Form S-8, File Nos. 333-03896, 333-116011, 333-137687 and 333-152670 filed by the Registrant on April 23, 1996, May 28, 2004, September 29, 2006 and July 31, 2008, respectively, relating to the Registrant's 1995 Employee Stock Purchase Plan.

**Item 5. Interests of Named Experts and Counsel.**

Wilmer Cutler Pickering Hale and Dorr LLP ( WilmerHale ) has opined as to the legality of the securities being offered by this registration statement.

**Item 8. Exhibits.**

The Exhibit Index immediately preceding the exhibits is incorporated herein by reference.

- 2 -

---

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Cambridge, Massachusetts on this 5<sup>th</sup> day of August, 2011.

IDERA PHARMACEUTICALS, INC.

By: /s/ Sudhir Agrawal  
 Sudhir Agrawal, D. Phil.  
 Chief Executive Officer

**POWER OF ATTORNEY AND SIGNATURES**

We, the undersigned officers and directors of Idera Pharmaceuticals, Inc., hereby severally constitute and appoint Sudhir Agrawal and Louis J. Arcudi, III, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Idera Pharmaceuticals, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

<b>Signature</b>	<b>Title</b>	<b>Date</b>
/s/ Sudhir Agrawal Sudhir Agrawal, D. Phil.	Chairman, President and Chief Executive Officer (Principal Executive Officer)	August 5, 2011
/s/ Louis J. Arcudi, III Louis J. Arcudi, III	Senior Vice President of Operations, Chief Financial Officer, Treasurer and Secretary (Principal Financial Officer)	August 5, 2011
/s/ Youssef El Zein Youssef El Zein	Director	August 5, 2011
/s/ C. Keith Hartley C. Keith Hartley	Director	August 5, 2011

<b>Signature</b>	<b>Title</b>	<b>Date</b>
/s/ Robert W. Karr Robert W. Karr, M.D.	Director	August 4, 2011
/s/ Malcolm MacCoss Malcolm MacCoss, Ph.D.	Director	August 4, 2011
/s/ Hans Mueller Hans Mueller, Ph.D.	Director	August 4, 2011
/s/ William S. Reardon William S. Reardon, C.P.A.	Director	August 5, 2011
/s/ Eve E. Slater Eve E. Slater, M.D., F.A.C.C.	Director	August 5, 2011
James B. Wyngaarden, M.D.	Director	

**INDEX TO EXHIBITS**

Number	Description
4.1(1)	Specimen Certificate for shares of Common Stock, \$0.001 par value, of Idera Pharmaceuticals, Inc.
4.2(2)	Rights Agreement dated December 10, 2001 by and between Idera Pharmaceuticals, Inc. and Mellon Investor Services LLC, as rights agent.
4.3(3)	Amendment No. 1 to Rights Agreement dated as of August 27, 2003 between Idera Pharmaceuticals, Inc. and Mellon Investor Services LLC, as rights agent.
4.4 (4)	Amendment No. 2 to Rights Agreement dated as of March 24, 2006 between Idera Pharmaceuticals, Inc. and Mellon Investor Services LLC, as rights agent.
4.5 (5)	Amendment No. 3 to Rights Agreement dated January 16, 2007 between Idera Pharmaceuticals, Inc. and Mellon Investor Services, LLC, as rights agent.
5.1	Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the Registrant
23.1	Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1)
23.2	Consent of Ernst & Young LLP
24.1	Power of attorney (included on the signature pages of this registration statement)
(1)	Previously filed with the Securities and Exchange Commission as an Exhibit to the Registration Statement on Form S-1, dated December 8, 1995 (File No. 33-99024) and incorporated herein by reference.
(2)	Previously filed with the Securities and Exchange Commission as an Exhibit to the Registrant's Registration Statement on Form S-2, dated October 10, 2003 (File No. 333-109630) and incorporated herein by reference.
(3)	Previously filed with the Securities and Exchange Commission as an Exhibit to the Registrant's Current Report on Form 8-K, dated August 29, 2003 (File No. 000-27352) and incorporated herein by reference.
(4)	Previously filed with the Securities and Exchange Commission as an Exhibit to the Registrant's Current Report on Form 8-K, dated March 29, 2006 (File No. 001-31918) and incorporated herein by reference.

- (5) Previously filed with the Securities and Exchange Commission as an Exhibit to the Registrant's Current Report on Form 8-K, dated January 17, 2007 (File No. 001-31918) and incorporated herein by reference.

- 6 -